Evogen and LGC have signed a licence agreement for LGC's Hybeacons PCR probe, that will augment Evogen's rapid molecular diagnostics and detection platform, which includes the Evocycler HD12.
Hybeacons probes are short fluorescently labelled DNA sequences that can be designed to detect sections of DNA sequence with a genetic variation.
The central location of the fluorescent molecule offers advantages over probes where signalling chemistry is located at the end of the DNA probe.
LGC developed Hybeacons probes in response to forensic and medical requirements to identify key genetic differences between individuals, and to distinguish micro-organisms.
The probes are suitable for rapid diagnostic and point-of-care applications.
Hybeacons assays have been designed for use in medical, genetic and infectious diagnostic testing.
Evogen's Evocycler HD12 molecular diagnostics instrument combines rapid amplification and detection within a single integrated platform.
The Evocycler HD12 was designed for clinical, research, environmental and biodefense applications.
It can process 12 samples in less than 30 minutes.
Its software automates key tasks, such as selecting the most appropriate primers and thermal cycling conditions through to auto-calling of results.
